Felicia Visit 1: A Middle-Aged Woman Presenting with Exertional Dyspnea
| Title: | Felicia Visit 1: A Middle-Aged Woman Presenting with Exertional Dyspnea |
| Topic: | Pulmonary Disease |
| Relevant Terms: | Cardiology, Pulmonary Critical Care Medicine |
| Primary Audience: | Cardiologists, Critical Care Physicians, Pulmonologists |
| Launch Date: | 03-Jan-13 |
| Credits: | 0.5 AMA PRA Category 1 Credit™ |
| Expiration Date: | 03-Jan-14 |
| Curriculum Name: | Improving the Quality of Patient Care in Pulmonary Hypertension |
Learning Objectives
After completing this activity, the participant will demonstrate the ability to:
- Follow guideline recommendations for use of multiple diagnostic tests to accurately diagnosis PAH.
- Compare the risks and benefits of PAH therapeutic options for individual patients.
- Select preferred treatment options based on guidelines for the most critically ill patients with PAH.
- Outline current evidence regarding combination treatment approaches for patients with PAH.
Faculty
Vallerie V. McLaughlin, MD
Professor of Internal Medicine, Division of Cardiovascular Medicine
Director, Pulmonary Hypertension Program
University of Michigan
Ann Arbor, MI
Aryeh Fischer, MD
Associate Professor of Medicine
Division of Rheumatology
University of Colorado Denver
Interstitial Lung Disease Program
National Jewish Health
Denver, CO
Michael A. Mathier, MD
Assistant Professor of Medicine
Director, Pulmonary Hypertension Program
Associate Director, Cardiovascular Fellowship Program
University of Pittsburgh
Pittsburgh, PA
Professor of Internal Medicine, Division of Cardiovascular Medicine
Director, Pulmonary Hypertension Program
University of Michigan
Ann Arbor, MI
Aryeh Fischer, MD Associate Professor of Medicine
Division of Rheumatology
University of Colorado Denver
Interstitial Lung Disease Program
National Jewish Health
Denver, CO
Michael A. Mathier, MDAssistant Professor of Medicine
Director, Pulmonary Hypertension Program
Associate Director, Cardiovascular Fellowship Program
University of Pittsburgh
Pittsburgh, PA
Disclosure Statements
In accordance with the Accreditation Council for Continuing Medical Education, National Jewish Health requires that all persons in a position to control the content of a CME activity, including the CME review committee, disclose all significant financial interest with commercial interests.
Dr. McLaughlin discloses that she served as a consultant for: Actelion Pharmaceuticals, Ltd; Bayer HealthCare Pharmaceuticals; Gilead Sciences, Inc.; and United Therapeutics Corporation. She served as a speaker or a member of a speakers bureau for: Actelion Pharmaceuticals, Ltd; Gilead Sciences, Inc.; United Therapeutics Corporation. She has received grants for clinical research from: Actelion Pharmaceuticals, Ltd; Gilead Sciences, Inc.; Novartis Pharmaceuticals Corporation; United Therapeutics Corporation.
Dr. Fischer discloses that he has received grant support from Gilead Sciences, and has served as a consultant and on the advisory board for Actelion Pharmaceuticals Ltd.
Dr. Mathier discloses that he has served as a consultant for Actelion Pharmaceuticals Ltd., Gilead Sciences, and United Therapeutics, and has received grant funding from Actelion Pharmaceuticals Ltd. and Forest Pharmaceuticals, Inc.
Activity planners and reviewers have no conflicts of interest to disclose.
Accreditation and Designation Statements
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of National Jewish Health and MCM Education. National Jewish Health is accredited by the ACCME to provide continuing medical education for physicians.
National Jewish Health designates this enduring material activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Release Date: January 3, 2013
Expiration Date: January 3, 2014
Instructions for Participating in this Activity and Obtaining CME Credit
Commercial Support Statement
This activity was supported by educational grants from Actelion Pharmaceuticals Ltd. and United Therapeutics Corporation.
Continuing Medical Education Disclaimer
National Jewish Health ("NJH") and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, "NJH Parties") shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.
By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.
Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.
In accordance with the Accreditation Council for Continuing Medical Education, National Jewish Health requires that all persons in a position to control the content of a CME activity, including the CME review committee, disclose all significant financial interest with commercial interests.
Dr. McLaughlin discloses that she served as a consultant for: Actelion Pharmaceuticals, Ltd; Bayer HealthCare Pharmaceuticals; Gilead Sciences, Inc.; and United Therapeutics Corporation. She served as a speaker or a member of a speakers bureau for: Actelion Pharmaceuticals, Ltd; Gilead Sciences, Inc.; United Therapeutics Corporation. She has received grants for clinical research from: Actelion Pharmaceuticals, Ltd; Gilead Sciences, Inc.; Novartis Pharmaceuticals Corporation; United Therapeutics Corporation.
Dr. Fischer discloses that he has received grant support from Gilead Sciences, and has served as a consultant and on the advisory board for Actelion Pharmaceuticals Ltd.
Dr. Mathier discloses that he has served as a consultant for Actelion Pharmaceuticals Ltd., Gilead Sciences, and United Therapeutics, and has received grant funding from Actelion Pharmaceuticals Ltd. and Forest Pharmaceuticals, Inc.
Activity planners and reviewers have no conflicts of interest to disclose.
Accreditation and Designation Statements
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of National Jewish Health and MCM Education. National Jewish Health is accredited by the ACCME to provide continuing medical education for physicians.
National Jewish Health designates this enduring material activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Release Date: January 3, 2013
Expiration Date: January 3, 2014
Instructions for Participating in this Activity and Obtaining CME Credit
There are no fees for participating in and receiving CME credit for this online educational activity. By reviewing the course content and successfully completing the post-test and evaluation, clinicians are entitled to receive credit. The statement of credit will be available to print from your user history page.
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the post-test and activity evaluation.
- Clinicians who successfully complete the post-test and evaluation will receive a CME certificate; successful completion is defined as a cumulative score of at least 80% correct on the post-test.
- All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
Estimated Time to Complete
30 minutes
Viewing Requirements
PC
Internet Explorer (v7 or greater), Google Chrome, or Firefox
Mac
Safari, Google Chrome, or Firefox
PC
Internet Explorer (v7 or greater), Google Chrome, or Firefox
Mac
Safari, Google Chrome, or Firefox
Commercial Support Statement
This activity was supported by educational grants from Actelion Pharmaceuticals Ltd. and United Therapeutics Corporation.
Continuing Medical Education Disclaimer
National Jewish Health ("NJH") and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, "NJH Parties") shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.
By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.
Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.
